References
- Herrick AL. Raynaud’s phenomenon. J Scleroderma Relat Disord 2019;4:89–101.
- Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology 2011;50:762–7.
- Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud’s phenomenon, as judged by patient perception. Rheumatology 2015;54:1443–7.
- Wilkinson J. Design and reporting of randomised controlled trials for Raynaud’s phenomenon. In: Wigley RM, Herrick AL, Flavahan NA, editors. Raynaud’s phenomenon: a guide to pathogenesis and treatment. New York: Springer, 2015:287–97.
- Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;46:2410–20.
- Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud’s phenomenon clinical trials. Arthritis Care Res 2013;65:630–6.
- Denton CP, Hachulla E, Riemekasten G, Schwarting A, Frenoux J, Frey A, et al. Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis. A randomized, placebo-controlled, Phase II study. Arthritis Rheumatol 2017;69:2370–9.
- Herrick AL, Dinsdale G, Murray A. New perspectives in the imaging of Raynaud’s phenomenon. Eur J Rheumatol 2020;7:S212–221.
- Pauling JD, Hackett N, Guida A, Merkel PA. Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: a systematic literature review. Semin Arthritis Rheum 2020;50:1114–30.
- Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor M, Valentini G, Furst D. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630–47.
- Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, et al. A multicentre study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud’s phenomenon. Arthritis Rheumatol 2018;70:903–11.
- Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199–206.
- Schioppo T, Orenti A, Boracchi P, De Lucia O, Murgo A, Ingegnoli F. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial. Rheumatology 2018;57:1408–16.
- Martin EC, Gasparini A, Crowther MJ. Merlin – an R package for mixed effects regression of linear, non-linear and user-defined models. (https://cran.r-project.org/web/packages/merlin/index.html)
- Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, et al. Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res 2018;70:1373–84.